Alimera Sciences, Inc. – NASDAQ:ALIM
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 1 hour
Alimera Sciences stock price monthly change
+79.49%
month
Alimera Sciences stock price quarterly change
+43.59%
quarter
Alimera Sciences stock price yearly change
+95.80%
year
Alimera Sciences key metrics
Market Cap | 301.28M |
Enterprise value | 53.39M |
P/E | -0.7 |
EV/Sales | 0.66 |
EV/EBITDA | -3.69 |
Price/Sales | 0.17 |
Price/Book | -0.68 |
PEG ratio | N/A |
EPS | -1.46 |
Revenue | 90.21M |
EBITDA | -393K |
Income | -21.41M |
Revenue Q/Q | 69.87% |
Revenue Y/Y | 61.74% |
Profit margin | -33.71% |
Oper. margin | -22.03% |
Gross margin | 85.34% |
EBIT margin | -22.03% |
EBITDA margin | -0.44% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAlimera Sciences stock price history
Alimera Sciences stock forecast
Alimera Sciences financial statements
| Jun 2023 | 17.53M | -10.02M | -57.18% |
|---|---|---|---|
| Sep 2023 | 23.36M | -1.35M | -5.8% |
| Dec 2023 | 26.30M | -3.78M | -14.37% |
| Mar 2024 | 23.01M | -6.25M | -27.17% |
| Sep 2025 | 29.1M | 1.08M | 3.74% |
|---|---|---|---|
| Oct 2025 | 29.96M | 1.90M | 6.35% |
| Dec 2025 | 33.03M | 5.97M | 18.1% |
| Mar 2026 | 28.6M | -1.63M | -5.71% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | |
| 2023 | 1.14% |
| Jun 2023 | 154923000 | 108.69M | 70.16% |
|---|---|---|---|
| Sep 2023 | 154192000 | 105.35M | 68.33% |
| Dec 2023 | 153524000 | 107.35M | 69.93% |
| Mar 2024 | 152485000 | 111.83M | 73.34% |
| Jun 2023 | -5.99M | -75.43M | 87.12M |
|---|---|---|---|
| Sep 2023 | -9.82M | -4K | -546K |
| Dec 2023 | 3.77M | -85K | -78K |
| Mar 2024 | -566K | -21K | 2.96M |
Alimera Sciences alternative data
| Aug 2023 | 150 |
|---|---|
| Sep 2023 | 150 |
| Oct 2023 | 150 |
| Nov 2023 | 150 |
| Dec 2023 | 150 |
| Jan 2024 | 150 |
| Feb 2024 | 150 |
| Mar 2024 | 154 |
| Apr 2024 | 154 |
| May 2024 | 154 |
| Jun 2024 | 154 |
| Jul 2024 | 154 |
Alimera Sciences other data
5.96%
-26.39%
of ALIM is owned by hedge funds
416.71K
-1.84M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 0 | 1200000 |
| May 2023 | 1417018 | 0 |
| Sep 2023 | 579000 | 579000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | CALIGAN PARTNERS LP 10 percent owner | Common Stock | 579,000 | $3.39 | $1,962,810 | ||
Sale | CALIGAN PARTNERS LP 10 percent owner | Common Stock, par value 0.01 per share (Common Stock) | 579,000 | $3.39 | $1,962,810 | ||
Purchase | MORGAN ADAM director, 10 percent owner: | Common Stock | 1,401,901 | $1.7 | $2,383,232 | ||
Purchase | MORGAN ADAM director, 10 percent owner: | Series B Convertible Preferred Stock | 8,117 | $1.7 | $13,799 | ||
Purchase | MORGAN ADAM director, 10 percent owner: | Series B Convertible Preferred Stock | 7,000 | $1.7 | $11,900 | ||
Sale | PALO ALTO INVESTORS LP 10 percent owner | Series A Convertible Preferred Stock | 1,200,000 | $1.56 | $1,875,600 | ||
Sale | MORGAN STANLEY 10 percent owner | Common Stock | 250,000 | $4.55 | $1,137,500 | ||
Purchase | EISWIRTH RICHARD S JR director, officer.. | Common Stock | 484 | $4.5 | $2,177 | ||
Purchase | EISWIRTH RICHARD S JR director, officer.. | Common Stock | 5,000 | $4.8 | $23,980 | ||
Purchase | EISWIRTH RICHARD S JR director, officer.. | Common Stock | 5,000 | $4.89 | $24,430 |
| Patent |
|---|
Application Filling date: 2 May 2019 Issue date: 7 Nov 2019 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 26 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Richard S. Eiswirth Jr. (1968) Pres, Chief Executive Officer & Director | $630,370 |
| Mr. David R. Holland (1964) Co-Founder, Chief Marketing Officer and Senior Vice President of Corporation Communications & Managed Markets | $429,360 |
| Dr. Philip Ashman (1965) Chief Operating Officer & Senior Vice President of Commercial Operations - Europe | $417,140 |
Mr. Charles Daniel Myers (1954) Non-Executive Chairman & Consultant | $205,000 |
-
When is Alimera Sciences's next earnings date?
Unfortunately, Alimera Sciences's (ALIM) next earnings date is currently unknown.
-
Does Alimera Sciences pay dividends?
No, Alimera Sciences does not pay dividends.
-
How much money does Alimera Sciences make?
Alimera Sciences has a market capitalization of 301.28M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 49.19% to 80.75M US dollars.
-
What is Alimera Sciences's stock symbol?
Alimera Sciences, Inc. is traded on the NASDAQ under the ticker symbol "ALIM".
-
What is Alimera Sciences's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Alimera Sciences?
Shares of Alimera Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Alimera Sciences's key executives?
Alimera Sciences's management team includes the following people:
- Mr. Richard S. Eiswirth Jr. Pres, Chief Executive Officer & Director(age: 57, pay: $630,370)
- Mr. David R. Holland Co-Founder, Chief Marketing Officer and Senior Vice President of Corporation Communications & Managed Markets(age: 61, pay: $429,360)
- Dr. Philip Ashman Chief Operating Officer & Senior Vice President of Commercial Operations - Europe(age: 60, pay: $417,140)
- Mr. Charles Daniel Myers Non-Executive Chairman & Consultant(age: 71, pay: $205,000)
-
Is Alimera Sciences founder-led company?
Yes, Alimera Sciences is a company led by its founder Mr. David R. Holland.
-
How many employees does Alimera Sciences have?
As Jul 2024, Alimera Sciences employs 154 workers.
-
When Alimera Sciences went public?
Alimera Sciences, Inc. is publicly traded company for more then 5 years since IPO on 4 Nov 2019.
-
What is Alimera Sciences's official website?
The official website for Alimera Sciences is alimerasciences.com.
-
Where are Alimera Sciences's headquarters?
Alimera Sciences is headquartered at 6310 Town Square, Alpharetta, GA.
-
How can i contact Alimera Sciences?
Alimera Sciences's mailing address is 6310 Town Square, Alpharetta, GA and company can be reached via phone at +678 990 5740.
Alimera Sciences company profile:
Alimera Sciences, Inc.
alimerasciences.comExchange:
NASDAQ
Full time employees:
154
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
6310 Town Square
Alpharetta, GA 30005
Alpharetta, GA 30005
CIK: 0001267602
ISIN: US0162592028
CUSIP: 016259202
